Compass Therapeutics, Inc. (CMPX)
(Delayed Data from NSDQ)
$1.41 USD
+0.05 (3.68%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.42 +0.01 (0.71%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CMPX 1.41 +0.05(3.68%)
Will CMPX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know
Compass Therapeutics, Inc. (CMPX) Loses -28.57% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CMPX
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
Compass Therapeutics Announces CEO Transition
Compass Therapeutics Announces CEO Transition and New Leadership
Compass Therapeutics names Thomas Schuetz as CEO
Compass Therapeutics CEO Vered Bisker-Leib steps down, Thomas Schuetz succeeds